Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant in trigeminal neuralgia (Phase II/III run-in + randomized double-blind)
2021-001866-39Phase 2Active
- Sponsor
- Noema Pharma
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of basimglurant in trigeminal neuralgia (TN) (3 arms), sponsored by Noema Pharma. Primary endpoints: Safety of basimglurant daily dosing (1.5–3.5 mg) during run-in and Efficacy of basimglurant on pain associated with trigeminal neuralgia during run-in. Started Oct 2021; status: active.
02
Drugs
basimglurant
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on 2021-001866-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001866-39.